ABSTRACT
Objective The goal of this research is to predict the most likely metastatic site(s) of a primary prostate cancer tumor that has been resected via radical prostatectomy; its genome has been sequenced to obtain a list of gene mutations; and after initial inspection of pelvic lymph nodes, there is no clinical evidence of metastasis. However, micrometastases might already be growing in distant organs and cannot be detected at the time of surgery.
Background The most common metastatic targets in prostate cancer (PCa) are the pelvic lymph nodes (PLN) and bones. The PLNs are routinely dissected by a procedure called pelvic lymph node dissection (PLND) simultaneously with the surgical removal of the prostate to detect the presence of metastatic growths. Additionally, the prostate-specific antigen (PSA) level is used to assess the existence of a metastatic stage. However, micrometastases in other organs and tissues might be overlooked.
Methods We downloaded publicly available prostate cancer tumor data from the website www.CbioPortal.org.
After choosing the 25 most commonly mutated genes by metastatic site (MS) and finding genes that are uniquely mutated on specific metastatic sites, we found that the mutational signature of a prostate cancer tumor is associated with its MS, and thus, we developed a method to numerically predict this association.
Results After executing a computational algorithm on the data set of metastatic prostate tumors, it was found that we can predict metastatic sites with the following accuracies: bone (90.9%), retroperitoneum (87.5%), liver (83.0%), kidney (80.0%), pancreas (80.0%), adrenal glands (75.0%), lung (71.1%), and brain (72.5%).
Conclusions We successfully developed a method and an algorithm that predict the most likely metastatic site of a primary prostate cancer tumor based on its genetic mutations. The accuracy of the predictions for eight metastatic sites ranges from 71.1% to 90.9%, with an average of 80.5%.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study did not receive any funding
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Data are publicly available at cBioPortal.org
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Contact: pgomez{at}nano-bio-tek.com
Data Availability
All data produced are available online at prostate.nano-bio-tek.com
